Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China

NEXT STORY
Press release Biocartis Group NV: BIOCARTIS KONDIGT 2019 RESULTATEN EN 2020 VOORUITZICHTEN AAN
PREV STORY
Press Release Biocartis Group NV: Biocartis Creates New Share Option Plan & Cancels Outstanding Pool under 2018 Share Option Plan
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cancer Genetics, Inc. Announces a Global Partnership with BARC Global Central Laboratory to Offer Comprehensive Clinical Trial and Companion Diagnostic Solutions for the Oncology Industry

The companies have entered into an agreement to offer biotech and pharmaceutical companies access ...

author_avatar
NASDAQ Market News

CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

BASEL, Switzerland and CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics, (NASDAQ:CRSP), ...

author_avatar
NASDAQ Market News

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to ...

author_avatar
NASDAQ Market News